Fitness Tracker

Jonathan Greenberg et al. (2025) · JAMA network open

This feasibility randomized clinical trial with 92 sedentary adults experiencing chronic musculoskeletal pain explored whether a mind-body walking program could be delivered successfully across three geographically and racially diverse U.S. academic medical centers, compared with a health education program. The mind-body walking program combined quota-based pacing — increasing step-count goals gradually based on what participants could sustain, rather than tying goals to whether pain was present — with mind-body skills such as breathing exercises and body scans, and cognitive skills aimed at identifying and reframing unhelpful pain-related thoughts. The trial measured physical function in three complementary ways (self-reported, performance-based, and step-count-based), addressing a gap identified in pain-trial reporting guidelines. Participants were randomized 1:1 to the 10-week, 60-minute weekly group mind-body walking program (47 participants) or a matched health-education control (45 participants), recruited between April 2023 and January 2024. The mind-body group received a Fitbit Inspire 3 tracker with individualized weekly step goals. Physical function was measured with the 6-Minute Walk Test, a wrist-worn accelerometer worn for one week, and the World Health Organization Disability Assessment Schedule. Pain, mood, and psychological mechanisms — pain catastrophizing, fear of movement, adaptive coping, and mindfulness — were measured with validated questionnaires before and after the program. Both programs met most feasibility benchmarks, including attendance (95.7% mind-body walking vs 82.2% health education), delivery fidelity, and participant retention (93.6% vs 86.7%). Racial and ethnic diversity exceeded its target (54.3% of participants from minority groups, against a 38% benchmark), though overall recruitment fell short (69.7% of eligible patients enrolled, against an 80% target). Within the mind-body walking group, participants showed large pre-to-post improvements in walking distance (48.6 meters over six minutes, P<.001), self-reported physical function (P<.001), and pain catastrophizing (P<.001), plus medium improvements in pain intensity (P=.002) and fear of movement (P<.001), and smaller but significant improvements in adaptive coping and mindfulness (both P<.05). The health education group improved only on walking distance and pain intensity. Because the trial was not statistically powered to compare the two programs against each other, these within-group changes describe what happened in each arm rather than a demonstrated advantage of one program over the other. The trial establishes that a mind-body walking program can be delivered with strong attendance and participant satisfaction across diverse academic medical centers, supporting a future, fully powered efficacy trial. The findings do not establish that the mind-body walking program produces greater benefit than health education, since the study was designed to test feasibility rather than comparative outcomes. The gap between eligible and enrolled participants (69.7% versus an 80% target) points to recruitment timing as an area for refinement in future trial designs.

Nathalie Schicktanz et al. (2025) · Brain and behavior

This randomized, double-blind, placebo-controlled trial with 40 completers explored whether Ze 91019, a fixed extract combination of valerian root (Valeriana officinalis) and hops (Humulus lupulus), could improve sleep in adults with occasional insomnia — sleep disturbances happening once or twice a week rather than a full clinical insomnia diagnosis — without the grogginess or memory problems that often accompany prescription sleep medications like benzodiazepines. Valerian and hops are long-used botanical sleep aids; in this fixed combination they are thought to act on the brain's adenosine system, the same pathway caffeine blocks, which governs how sleepy or alert the brain feels. Forty-one healthy adults aged 18-65 with occasional sleep problems and subjective cognitive complaints were randomized at the University of Basel, Switzerland, to either Ze 91019 or placebo for 21 nights, after a 21-day baseline period. Each night, participants took one tablet, 500 mg valerian extract plus 120 mg hops extract, about an hour before bed. A Fitbit Charge 5 wristband tracked sleep duration and heart rate continuously, while daily online tests measured reaction time and working memory (digit span backward), and visual analog scales captured mood, stress, tiredness, and sleep quality. The study design itself worked well, with adherence above 89% for surveys and medication and above 96% for the wearable tracker. Compared with placebo, Ze 91019 increased average nightly sleep duration by 21.7 minutes (p = 0.019, a small-to-moderate effect) and lengthened time in bed by 24.4 minutes (p = 0.023). The benefit was largest on each person's shortest night of sleep, where Ze 91019 added 48.7 minutes of sleep versus placebo (p = 0.016), suggesting the extract may help most when sleep is already restricted. Despite the sleep gains, daytime reaction time, working memory, and self-rated mood, stress, and cognitive performance did not differ significantly between groups (p ≥ 0.26), meaning the extra sleep did not translate into measurable next-day cognitive or emotional change. Twenty-nine mild-to-moderate adverse events occurred overall, somewhat more often with Ze 91019 than placebo, but the difference was not statistically significant, and no serious adverse events occurred. These results support Ze 91019 as a generally well-tolerated option for occasional sleep difficulty that does not appear to blunt next-day thinking or mood, unlike many conventional hypnotics. However, this was explicitly a feasibility study with no formal power calculation, exploratory statistics, and only 40 completers at a single site, so the sleep-duration effect needs confirmation in a larger, adequately powered trial. Because valerian and hops were tested only as a fixed combination, the individual contribution of each herb remains unclear, and longer studies are needed to see whether cognitive benefits emerge over time.